恆瑞醫藥與 Glenmark Specialty 公司簽署瑞康曲妥珠單抗項目授權許可協議
Hengrui Pharma signed a licensing agreement with Glenmark Specialty, granting a paid license for the SHR-A1811 project (RuiKang Trastuzumab) to Glenmark Specialty. Hengrui has granted Glenmark Specialty exclusive rights to develop and commercialize the drug in multiple countries and regions, with an upfront payment of $18 million and potential milestone payments and sales royalties of up to $1.093 billion. This agreement will expand the overseas market for RuiKang Trastuzumab and enhance the company's innovative brand and performance
According to the news from Zhitong Finance APP, Hengrui Pharma (01276) announced that the company has reached an agreement with Glenmark Specialty S.A. (hereinafter referred to as "Glenmark Specialty") to grant a paid license for its independently developed Class 1 innovative drug SHR-A1811 (RuiKang Trastuzumab) project to Glenmark Specialty.
According to the agreement, Hengrui will grant Glenmark Specialty exclusive rights to develop and commercialize RuiKang Trastuzumab globally, except for mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan, the United States, Canada, Europe, Japan, Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Uzbekistan. Glenmark Specialty will pay Hengrui an upfront payment of $18 million, and Hengrui will be eligible to receive milestone payments related to registration and sales, totaling up to $1.093 billion. Based on the sales performance of RuiKang Trastuzumab within the licensed scope, Glenmark Specialty will pay Hengrui corresponding sales commissions.
The signing of this agreement will help expand the overseas market for RuiKang Trastuzumab, providing high-quality treatment options for patients worldwide, and will further enhance the company's innovative brand and overseas performance. The company insists on balancing independent research and development with open cooperation, strengthening international collaboration based on endogenous development, achieving rapid transformation of research and development results, leveraging internationally leading partners to cover overseas markets, accelerating integration into the global drug innovation network, maximizing product value, and serving global patients with innovative products
